Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The MoU underscores a shared commitment to strengthening Abu Dhabi’s position as a global hub for healthcare innovation ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Dixon Technologies' outperform rating is sustained by BNP Paribas India, citing remarkable FY25 results and future ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer ... contribute to a stable global vaccine supply, and achieve ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials ... testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about ...

In 2020, Pfizer claimed ... transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...